Chinese Hepatolgy ›› 2026, Vol. 31 ›› Issue (9): 1263-1266.

• Viral Hepatit • Previous Articles     Next Articles

The effectiveness and safety of tenofovir disoproxil fumarate combined with neonatal dual immunoprophylaxis in preventing mother-to-child HBV transmission

Ge Chunyan1, Cao Xia1, Youlituziayi Adili2, You Chunxia1   

  1. 1. Department of Obstetrics and Gynecology, Nantong Third People's Hospital, Nantong 226000, China;
    2. Department of Obstetrics, People's Hospital of Kizilsu Kirghiz Autonomous Prefecture, Artux 845350, China
  • Received:2026-01-16 Online:2026-09-30 Published:2026-11-16
  • Contact: You Chunxia,Email: youyu2008009@163.com

Abstract: Objective To investigate the effectiveness and safety of tenofovir disoproxil fumarate (TDF) combined with neonatal dual immunoprophylaxis in preventing mother-to-child transmission of hepatitis B virus (HBV) among HBsAg-positive pregnant women with high viral loads. Methods A total of 94 HBsAg-positive pregnant women and their infants who received antenatal care and delivered at Nantong Third People's Hospital were enrolled. According to whether antiviral therapy was administered during pregnancy, all participants were divided into a combined prophylaxis group (n=43) and a standard prophylaxis group (n=51). The pregnant women in the combined group received oral TDF during mid-to-late pregnancy, whereas those in the standard group did not receive antiviral therapy. All newborns in both groups received hepatitis B immunoglobulin (HBIG) within 12 hours after birth and completed the full hepatitis B vaccination schedule at 0, 1, and 6 months. The HBV infection status of infants at 7~12 months of age, neonatal immune response, dynamic changes in maternal virological and biochemical parameters, and maternal and infant safety outcomes were compared between the two groups. Results At the 7~12 month follow-up, the rates of HBsAg and HBV DNA positivity were both 0 in the combined prophylaxis group, whereas 5 infants (9.8%) in the standard prophylaxis group were positive for HBsAg and/or HBV DNA (P<0.05). The median anti-HBs titer in infants was higher in the combined prophylaxis group than that in the standard group [356 (210, 620) mIU/mL vs. 185 (95, 402) mIU/mL, P<0.05], and the proportion of high-level immune response (≥1 000 mIU/mL) was greater (39.5% vs. 19.6%, P<0.05). At delivery, maternal HBV DNA levels were lower in the combined prophylaxis group than in the standard group [(3.2±1.1) lg IU/mL vs. (6.9±0.7) lg IU/mL, P<0.05], with a greater reduction in viral load [(4.4±1.1) lg IU/mL vs. (0.6±0.2) lg IU/mL, P<0.05]. There were no statistically significant differences between the two groups in maternal hepatic or renal dysfunction, pregnancy complications, or adverse neonatal outcomes (P>0.05). Conclusion Among HBsAg-positive pregnant women with high viral loads, TDF combined with neonatal dual immunoprophylaxis significantly reduces the rate of HBV mother-to-child transmission and improves the quality of neonatal immune responses to hepatitis B vaccination, without increasing maternal or neonatal adverse events, indicating a favorable clinical applicability.

Key words: Hepatitis B virus, Tenofovir disoproxil fumarate, Hepatitis B immunoglobulin, Hepatitis B vaccination, Mother-to-child transmission